Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Dupuytrens Disease Therapeutics Market

Dupuytrens Disease Therapeutics Market Share

Report ID: GMI10672
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Dupuytren’s Disease Market Share

The dupuytren’s disease therapeutics sector is highly competitive, featuring a blend of major global players and smaller to medium-sized companies vying for market share. The market is concentrated, with Endo International plc commanding significant share of the market, primarily through its product Xiaflex. Other competitors are focusing on alternative drugs and symptomatic treatments.

A key component of market strategy is the ongoing introduction of innovative products through diverse technologies. Leading industry players exert substantial influence, driving progress with significant investments in R&D. Additionally, strategic partnerships and M&A activities are vital for enhancing market presence and expanding global reach, particularly amidst evolving regulatory landscapes.

Dupuytren’s Disease Market Companies

Some of the eminent market participants operating in the dupuytren’s disease therapeutics industry include:

AstraZeneca PLC
Actiza Pharmaceutical Private Limited
Bayer AG
Bristol-Meyers Squibb Company
Endo International plc
Fresenius SE & Co. KGaA
Fortress Biotech, Inc.
GSK plc
Hikma Pharmaceuticals PLC
Johnson & Johnson
Merck & Co., Inc.
Nantong Jinghua Pharmaceutical Co., Ltd
Novartis AG
LEO Pharma A/S
Pfizer Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Dupuytren’s disease therapeutics market size was valued at around USD 889.4 million in 2023 and is estimated to grow at 12.2% CAGR from 2024 to 2032 owing to the rising prevalence for dupuytren's disease.

The collagenase injection segment of market accounted for USD 489.2 million in 2023 as they offer a minimally invasive treatment option.

Germany dupuytren’s disease therapeutics market is projected to reach USD 234.4 million by 2032 attributed to its strong emphasis on R&D activities.

AstraZeneca PLC, Actiza Pharmaceutical Private Limited, Bayer AG, Bristol-Meyers Squibb Company, Endo International plc, Fresenius SE & Co. KGaA, Fortress Biotech, Inc., and GSK plc among others.